Escherichia coli Infections – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Escherichia coli Infections – Pipeline Review, H2 2019’, provides an overview of the Escherichia coli Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Escherichia coli Infections

– The report reviews pipeline therapeutics for Escherichia coli Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Escherichia coli Infections therapeutics and enlists all their major and minor projects

– The report assesses Escherichia coli Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Escherichia coli Infections”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Escherichia coli Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Escherichia coli Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“ABAC Therapeutics SA

Abgentis Ltd

Affilogic SAS

AstraZeneca Plc

Atterx Biotherapeutics Inc

BB100 LLC

Biomendics LLC

Bugworks Research India Pvt Ltd

ContraFect Corp

Curza Global LLC

Debiopharm International SA

Eligo Bioscience SA

Eligochem Ltd

EnBiotix Inc

EveliQure Biotechnologies GmbH

F. Hoffmann-La Roche Ltd

Forge Therapeutics Inc

GlyProVac ApS

Hsiri Therapeutics LLC

Immuron Ltd

Johnson & Johnson

Kyorin Pharmaceutical Co Ltd

Linnaeus Bioscience Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Navigen Inc

Neoculi Pty Ltd

Northern Antibiotics Oy

Nosopharm SAS

Novabiotics Ltd

Oxford Drug Design Ltd

Paratek Pharmaceuticals Inc

Phico Therapeutics Ltd

Procarta Biosystems Ltd

Protein Potential LLC

Pylum Biosciences Inc

Recce Ltd

RemAb Therapeutics SL

Sealife PHARMA GMBH

Shanghai Space Peptides Pharmaceutical Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Syntiron LLC

TCM Biotech International Corp

Tetraphase Pharmaceuticals Inc

Venus Medicine Research Center”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Escherichia coli Infections Overview 6

Escherichia coli Infections Therapeutics Development 7

Escherichia coli Infections Therapeutics Assessment 18

Escherichia coli Infections Companies Involved in Therapeutics Development 27

Escherichia coli Infections Drug Profiles 42

Escherichia coli Infections Dormant Projects 165

Escherichia coli Infections Discontinued Products 169

Escherichia coli Infections Product Development Milestones 170

Appendix 181

List of Tables

“List of Tables

Number of Products under Development for Escherichia coli Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Escherichia coli Infections – Pipeline by ABAC Therapeutics SA, H2 2019

Escherichia coli Infections – Pipeline by Abgentis Ltd, H2 2019

Escherichia coli Infections – Pipeline by Affilogic SAS, H2 2019

Escherichia coli Infections – Pipeline by AstraZeneca Plc, H2 2019

Escherichia coli Infections – Dormant Projects, H2 2019

Escherichia coli Infections – Dormant Projects, H2 2019 (Contd..1), H2 2019

Escherichia coli Infections – Dormant Projects, H2 2019 (Contd..2), H2 2019

Escherichia coli Infections – Dormant Projects, H2 2019 (Contd..3), H2 2019

Escherichia coli Infections – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Escherichia coli Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports